2016
DOI: 10.1001/jamaneurol.2016.1810
|View full text |Cite
|
Sign up to set email alerts
|

Coenzyme Q10 as a Peripheral Biomarker for Multiple System Atrophy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(7 citation statements)
references
References 14 publications
0
7
0
Order By: Relevance
“…A notable example is represented by α-syn immunotherapy (both passive and active immunization), which has shown promising results in preclinical models of synucleinopathies [4, 31, 6769, 118] and is now under investigation in clinical trials. However, other pharmacological compounds which are not directly related to α-syn, but to independent pathogenic mechanisms, including inflammation [111, 124] and mitochondrial dysfunction [59], are under investigation.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…A notable example is represented by α-syn immunotherapy (both passive and active immunization), which has shown promising results in preclinical models of synucleinopathies [4, 31, 6769, 118] and is now under investigation in clinical trials. However, other pharmacological compounds which are not directly related to α-syn, but to independent pathogenic mechanisms, including inflammation [111, 124] and mitochondrial dysfunction [59], are under investigation.…”
Section: Discussionmentioning
confidence: 99%
“…The assessment of the activity level of respiratory chain complexes I + III and II + III in brain samples has not provided significant results, whereas the amount of the CoQ10 biosynthesis enzymes PDSS1 and COQ5 has been found to be reduced in patients’ brains. A reduction of CoQ10 level has also been described in patients’ cerebrospinal fluid [19] and plasma/serum [52, 59, 73].…”
Section: Mitochondriamentioning
confidence: 99%
“…However, based on pathological and molecular evidence from MSA human studies and animal models, several factors seem to be definitely associated with the disease and may serve as therapeutic targets for disease modification (Fig. 1), including the abnormal accumulation of α-syn [30][31][32][33]43,44], microglial activation and neuroinflammation [52,[54][55][56][57][58][59][60][61]89], autophagy disturbances [64][65][66][67], mitochondrial dysfunction [12,15,66,[68][69][70][71][72][73][74] and oxidative stress [76]. Yet the primary event which triggers the whole pathogenic cascade is still unknown.…”
Section: Discussionmentioning
confidence: 99%
“…Finally, MSA patients showed reduced levels of CoQ10 in cerebrospinal fluid, plasma/serum and cerebellum [68][69][70][71][72][73], which may lead to decreased electron transport in mitochondria and increased vulnerability to oxidative stress [68,69]. Recent studies with MSA fibroblast and iPSCs-derived dopaminergic neurons observed reduced CoQ10 levels and up-regulation of some CoQ10 biosynthesis enzymes in MSA patients compared to healthy controls [66,67,74].…”
Section: Other Translational Therapies For Msamentioning
confidence: 99%
See 1 more Smart Citation